Published in
Elsevier, The Lancet Infectious Diseases, 5(16), p. e76-e81, 2016
DOI: 10.1016/s1473-3099(16)00117-1
Links
Tools
Rethinking the risk–benefit ratio of efavirenz in HIV-infected children
Journal article published in 2016 by
Lisa Van de Wijer,
Arnt F. A. Schellekens 
,
David M. Burger,
Judith R. Homberg,
Quirijn de Mast ,
Andre J. A. M. van der Ven
,
David M. Burger,
Judith R. Homberg,
Quirijn de Mast ,
Andre J. A. M. van der Ven
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 